Home โบ Glioma
Glioma clinical trials recruiting in the U.S.
118 studies for Glioma are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY26 studies
- Houston, TX24 studies
- Boston, MA19 studies
- Washington, DC17 studies
- Philadelphia, PA15 studies
- Columbus, OH15 studies
- San Francisco, CA15 studies
- Miami, FL15 studies
- Durham, NC12 studies
- Chicago, IL12 studies
- Los Angeles, CA11 studies
- Aurora, CO10 studies
- Seattle, WA10 studies
- St. Louis, MO9 studies
- Edison, NJ8 studies
- Cincinnati, OH8 studies
- Rochester, MN8 studies
- Queens, NY6 studies
- Atlanta, GA6 studies
- Cleveland, OH6 studies
- Jacksonville, FL6 studies
- Orange, CA6 studies
- Baltimore, MD5 studies
- San Diego, CA5 studies
- Birmingham, AL5 studies
- Nashville, TN5 studies
- Ann Arbor, MI5 studies
- Staten Island, NY4 studies
- New Rochelle, NY4 studies
- Greenburgh, NY4 studies
- East Norwalk, CT4 studies
- Dallas, TX4 studies
- Indianapolis, IN4 studies
- New Haven, CT4 studies
- Mountain View, CA4 studies
- Arlington, VA4 studies
- Phoenix, AZ4 studies
- Winston-Salem, NC4 studies
- Omaha, NE4 studies
- Minneapolis, MN3 studies
By state
- Alabama5 studies
- Arizona7 studies
- California27 studies
- Colorado11 studies
- Connecticut6 studies
- District of Columbia13 studies
- Florida24 studies
- Georgia6 studies
- Illinois12 studies
- Indiana4 studies
- Maryland9 studies
- Massachusetts19 studies
- Michigan7 studies
- Minnesota12 studies
- Missouri10 studies
- Nebraska4 studies
- New Jersey11 studies
- New York28 studies
- North Carolina16 studies
- Ohio19 studies
- Pennsylvania18 studies
- Tennessee7 studies
- Texas26 studies
- Utah3 studies
- Virginia4 studies
- Washington10 studies
Recently updated studies
A Study of Mirdametinib in People With Central Nervous System Tumors
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Nov 13, 2026 ยท NCT07539441000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
RecruitingPhase 1/2
Ages 15 to 99 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT05588141Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 12, 2026 ยท NCT07326566Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
Recruiting
Ages 18 to 85 ยท All sexes ยท Updated Nov 12, 2026 ยท NCT06910306Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
RecruitingObservational study
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07927595A Phase I Clinical Study of YN003 in the Treatment of Glioma
RecruitingPhase 1
Ages 18 to 70 ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07929909Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Nov 10, 2026 ยท NCT07703436PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RecruitingPhase 1/2
Ages 18 to 120 ยท All sexes ยท Updated Nov 6, 2026 ยท NCT06161519A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT07464925Intratumoral Extracellular Metabolic Impact of DFMO and AMXT 1501 in Patients With Diffuse or High Grade Glioma
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Nov 4, 2026 ยท NCT05717153Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
RecruitingPhase 2
Up to age 3 ยท All sexes ยท Updated Nov 3, 2026 ยท NCT06528691Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being
Recruiting
Ages 18 and older ยท All sexes ยท Updated Nov 3, 2026 ยท NCT07628647Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Nov 2, 2026 ยท NCT05804227A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
RecruitingPhase 1
Ages 4 and older ยท All sexes ยท Updated Oct 30, 2026 ยท NCT04573140A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 27, 2026 ยท NCT05916313ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
RecruitingPhase 2
12 Months โ 39 Years ยท All sexes ยท Updated Oct 23, 2026 ยท NCT06838676Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT06810544Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Oct 21, 2026 ยท NCT05460507Development of MRF for Characterization of Brain Tumors After Radiotherapy
RecruitingHealthy volunteers welcome
Ages 18 to 60 ยท All sexes ยท Updated Oct 20, 2026 ยท NCT06101069Tumor Treating Fields for the Treatment of Brainstem Gliomas
Recruiting
Ages 18 and older ยท All sexes ยท Updated Oct 19, 2026 ยท NCT05310448SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
RecruitingPhase 3
Ages 18 and older ยท All sexes ยท Updated Oct 19, 2026 ยท NCT05303519Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
RecruitingPhase 1/2
Ages 18 to 99 ยท All sexes ยท Updated Oct 16, 2026 ยท NCT07416188Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
RecruitingPhase 1
Ages 18 to 120 ยท All sexes ยท Updated Oct 16, 2026 ยท NCT06344130A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Oct 16, 2026 ยท NCT06072586Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
Recruiting
Ages 18 and older ยท All sexes ยท Updated Oct 14, 2026 ยท NCT00870129From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.